Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 22;3(6):e305.
doi: 10.1097/HS9.0000000000000305. eCollection 2019 Dec.

MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)

Maria Chiara Tisi  1   2 , Simone Ferrero  3 , Irene Dogliotti  3 , Cristina Tecchio  4 , Giuseppe Carli  1 , Mattia Novo  5 , Piero Maria Stefani  6 , Sara Rattotti  7 , Monica Balzarotti  8 , Dario Marino  9 , Matteo Pelosini  10 , Alessandra Romano  11 , Leonardo Flenghi  12 , Vittorio Ruggero Zilioli  13 , Teresa Calimeri  14 , Arianna Di Napoli  15 , Manuela Zanni  16 , Erica Finolezzi  17 , Federico Mosna  6   18 , Guido Gini  19 , Giovanna Mansueto  20 , Alice Di Rocco  21 , Gabriella Tomei  22 , Nicola Sgherza  23 , Jacopo Olivieri  24   25 , Luca Nassi  26 , Francesco Piazza  27 , Angelo Fama  28 , Antonio Greco  29 , Margherita Giannoccaro  30 , Anna Maria Mazzone  31 , Carlo Visco  32 , Giacomo Loseto  33 , Francesco Zaja  25   34
Affiliations

MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)

Maria Chiara Tisi et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PFS by delivered treatment: 24 months PFS 65% (95% CI 49–68) in patients who received intensive treatments, 46% (95% CI 29–62) in those who received R-CHOP-like schedules (p = 0.04 compared with intensive and DA-EPOCH-R); 59% (95% CI 33–78) in patients treated with DA-EPOCH-R (p = 0.6, compared with intensive treatments) and not evaluable in patients treated with other treatments (p = 0.001).
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. - PMC - PubMed
    1. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354–2361. - PubMed
    1. McPhail ED, Maurer MJ, Macon WR, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018;103:1899–1907. - PMC - PubMed
    1. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5:e609–e617. - PMC - PubMed
    1. Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170:504–514. - PubMed